Genetic predictors of response to therapy in childhood asthma

Molecular Diagnosis and Therapy

Volumn 13, Issue 2, 2009, Pages 127-135

  Dunn, Lara ^a   DeMichele, Angela ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 14 Penn Tower   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; GLYCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; MONTELUKAST; SALBUTAMOL; SHORT ACTING DRUG;

ASTHMA; CHILDHOOD DISEASE; GENETIC VARIABILITY; HEREDITY; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TACHYPHYLAXIS; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; CHILD; HUMANS;

EID: 67650480217     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/01250444-200913020-00006     Document Type: Review

References (39)

1. Asthma UK. What is asthma? [online]. Available from URL: http://www. asthma.org.uk/all-about-asthma/asthma-basics/index.html [Accessed 2008 Jun 13]
2. McLeish S, Turner SW. Gene-environment interactions in asthma. Arch Dis Child 2007; 92: 1032-5
3. Carroll W.Asthma genetics: pitfalls and triumphs. Paediatr Respir Rev 2005; 6: 68-74
4. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-42
5. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52
6. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959; 12: 52-125
7. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99-111
8. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2: 485-91
9. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52
10. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56: 1054-70
11. de Marco R, Locatelli F, Sunyer J, et al. Differences in incidence of reported asthma related to age in men and women: a retrospective analysis of the data of the European Respiratory Health Survey. Am J Resp Crit Care Med 2000; 162 (1): 68-74
12. Watson JD, Baker TA, Bell SP, et al. Molecular biology of the gene. New York: Benjamin Cummings and Cold Spring Harbor Laboratory Press, 2004
13. Schork NJ, Fallin D, Lanchbury JS. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet 2000; 58: 250-64
14. van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30
15. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470-3
16. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-8
17. Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salme-terol. Thorax 2006; 61: 940-4
18. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13: 1353-9
19. Tantisira KG, Hwang ES, Raby BA, etal. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Nat Acad Sci U S A 2004; 101: 18099-104
20. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-12
21. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma, May 2008 [online]. Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.html [Accessed 2009 Mar 6]
22. Turner SW, Thomas M, von Ziegenweidt J, et al. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009 Jan; 94 (1): 16-22
23. Silverman EK, Kwiatkowski DJ, Sylvia JS, et al. Family-based association analysis of beta2-adrenergic receptor polymorphismsinthe childhoodasthma management program. J Allergy Clin Immunol 2003; 112: 870-6
24. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. Control Clin Trials 1999; 20: 91-120
25. Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25-33
26. Giubergia V, Gravina LP, Castaños C, et al. Influence of β2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol 2008; 43: 421-5
27. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55: 762-7
28. Carroll CL, Stoltz P, Schramm CM et al. β2-Adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009; 135: 1186-92
29. Poon AH, Tantisira KG, Litonjua AA, et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008; 18: 373-82
30. Litonjua AA, Lasky-Su L, Schneiter K, et al. ARG1 is a novel bronchodilator response gene. Am J Respir Crit Care Med 2008; 178: 688-94
31. Morris CR, Poljakovic M, Lavrisha L, et al. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004; 170: 148-53
32. Maarsingh H, Zuidhof AB, Bos IS, et al. Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am J Respir Crit Care Med 2008; 178: 565-73
33. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26
34. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmaco-genetic analysis of two randomised studies. Lancet 2007; 370: 2118-25
35. Tantisira KG, Small KM, Litonjua AA, et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14: 1671-7
36. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120: 1285-91
37. Drazen JM, Yandava CN, Dube L,et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics 1999; 22: 168-70
38. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.Am J Respir Crit Care Med 2006; 173: 379-85
39. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxy-genase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17: 189-96